Literature DB >> 1828618

Programmed cell death of T cells signaled by the T cell receptor and the alpha 3 domain of class I MHC.

S R Sambhara1, R G Miller.   

Abstract

As well as being activated or rendered unresponsive, mature T lymphocytes can be deleted, depending on the signals received by the cell. Deletion by programmed cell death (apoptosis) is triggered if a T cell that has received a signal through its T cell receptor complex also receives a signal through the alpha 3 domain of its class I major histocompatibility complex (MHC) molecule. Such a signal can be delivered by a CD8 molecule, which recognizes the alpha 3 domain, or by an antibody to this domain. Precursors of both cytotoxic T lymphocytes (CTL's) and T helper cells are sensitive to this signal but become resistant at some point before completing differentiation into functioning CTL's or T helper cells. Because CTL's carry CD8, they can induce cell death in T cells that recognize them. This pathway may be important in both removal of autoreactive T cells and immunoregulation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1828618     DOI: 10.1126/science.1828618

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  24 in total

Review 1.  Treatment of an autoimmune disease with "classical" T cell veto: a proposal.

Authors:  U D Staerz; Y Qi
Journal:  J Clin Immunol       Date:  1999-07       Impact factor: 8.317

Review 2.  Molecular and cellular mechanisms of donor cell-induced tolerance.

Authors:  James F George; Leonik Ahumada; Ailing Lu
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 3.  Separating antiviral and GVHD activities of donor T cells prior to bone marrow transplantation.

Authors:  Catherine T Jordan; John D Roback
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

4.  The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells.

Authors:  D Vremec; M Zorbas; R Scollay; D J Saunders; C F Ardavin; L Wu; K Shortman
Journal:  J Exp Med       Date:  1992-07-01       Impact factor: 14.307

5.  CTLs respond with activation and granule secretion when serving as targets for T-cell recognition.

Authors:  Oren Milstein; David Hagin; Assaf Lask; Shlomit Reich-Zeliger; Elias Shezen; Eran Ophir; Yaki Eidelstein; Ran Afik; Yaron E Antebi; Michael L Dustin; Yair Reisner
Journal:  Blood       Date:  2010-11-02       Impact factor: 22.113

6.  Cell-surface marker analysis of rat thymic dendritic cells.

Authors:  M P Bañuls; A Alvarez; I Ferrero; A Zapata; C Ardavin
Journal:  Immunology       Date:  1993-06       Impact factor: 7.397

7.  Inhibition of cytotoxic alloreactivity by human allogeneic mononuclear cells: evidence for veto function of CD2+ cells.

Authors:  G Raddatz; A Deiwick; T Sato; H J Schlitt
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

Review 8.  Role of the CTLA-4 receptor in T cell activation and immunity. Physiologic function of the CTLA-4 receptor.

Authors:  P Scheipers; H Reiser
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

Review 9.  New designs for cancer vaccine and artificial veto cells: an emerging palette of protein paints.

Authors:  Mark L Tykocinski; Aoshuang Chen; Jui-Han Huang; Matthew C Weber; Guoxing Zheng
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 10.  Immune tolerance and transplantation.

Authors:  Onder Alpdogan; Marcel R M van den Brink
Journal:  Semin Oncol       Date:  2012-12       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.